

---

**Product Data Sheet**


---

Product Name: CGP-53153

Cat. No.: GC32422

**Chemical Properties**

Cas. No. 149281-19-6

SMILES C[C@@]1([C@H]2C(NC(C)(C)C#N)=O)[C@](CC2)([H])[C@@](CC[C@](N3)([H])[C@@]4(C=CC3=O)C)([H])[C@]4([H])CC1

Formula	C <sub>23</sub> H <sub>33</sub> N <sub>3</sub> O <sub>2</sub>	M.Wt	383.53
---------	---	------	--------

Solubility	Soluble in DMSO	Storage	Store at -20°C
------------	-----------------	---------	----------------

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Animal experiment:**

Rats: Adult male rats weighing 160-180 g at the start of the study are treated orally once daily for 14 consecutive days either with increasing doses of CGP-53153 (1, 3 and 10 mg/kg) or with 10 mg/kg finasteride in 20% HCD. Control rats are given 20% HCD. On the 14th treatment day, 4 h after the last application, the animals are randomized and rapidly killed. Trunk blood is collected in polystyrene tubes and serum obtained by centrifugation is stored at -20°C for hormone (T, DHT and rat-LH) determination at a later date. After decapitation, the following organs are excised and weighed after removal of adhering fat and connective tissue: ventral prostate, seminal vesicles, levator ani and bulbocavernosus muscle, testes, pituitary, adrenals, thyroid, thymus and liver[1].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

---

## Product Data Sheet

---

### References:

[1]. Husler A, et al. CGP-53153: a new potent inhibitor of 5 $\alpha$ -reductase. J Steroid Biochem Mol Biol. 1996 Feb;57(3-4):187-95.

### Background

CGP-53153 is a steroidal inhibitor of 5  $\alpha$  reductase with IC<sub>50</sub>s of 36 and 262 nM in rat and human prostatic tissue, respectively.

CGP-53153 competitively inhibits rat microsomal 5  $\alpha$  reductase from prostate with an IC<sub>50</sub> of 36 nM compared to the reference compound finasteride (IC<sub>50</sub>=11 nM). CGP 53153 is approximately one order of magnitude more potent in inhibiting rat compared to human 5  $\alpha$  reductase, with IC<sub>50</sub> values of 36 and 262 nM, respectively

CGP-53153 can significantly reduce T-propionate-mediated prostate growth at oral doses of 0.01 mg/kg. CGP-53153 significantly reduces prostate weight at 3 and 10 mg/kg by 31% and 37%, respectively. Treatment for 12 weeks with both CGP-53153 reduces prostate volume by more than 70% in individual dogs. Neither body weight nor the weight of any organ tested is affected by CGP-53153[1].

[1]. Husler A, et al. CGP-53153: a new potent inhibitor of 5 $\alpha$ -reductase. J Steroid Biochem Mol Biol. 1996 Feb;57(3-4):187-95.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA